Phosphodiesterase III inhibitor promotes drainage of cerebrovascular β-amyloid.

ABSTRACT:

Objective

Brain amyloidosis is a key feature of Alzheimer's disease (AD). It also incorporates cerebrovascular amyloid β (Aβ) in the form of cerebral amyloid angiopathy (CAA) involving neurovascular dysfunction. We have recently shown by retrospective analysis that patients with mild cognitive impairment receiving a vasoactive drug cilostazol, a selective inhibitor of phosphodiesterase (PDE) III, exhibit significantly reduced cognitive decline. Here, we tested whether cilostazol protects against the disruption of the neurovascular unit and facilitates the arterial pulsation-driven perivascular drainage of Aβ in AD/CAA.

Methods

We explored the expression of PDE III in postmortem human brain tissue followed by a series of experiments examining the effects of cilostazol on Aβ m

SUBMITTER: Maki T 

PROVIDER: S-EPMC4184555 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature